1. Home
  2. PRT vs VERU Comparison

PRT vs VERU Comparison

Compare PRT & VERU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo PermRock Royalty Trust Trust Units

PRT

PermRock Royalty Trust Trust Units

HOLD

Current Price

$2.76

Market Cap

41.4M

Sector

Energy

ML Signal

HOLD

Logo Veru Inc.

VERU

Veru Inc.

HOLD

Current Price

$2.22

Market Cap

40.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PRT
VERU
Founded
2017
1971
Country
United States
United States
Employees
N/A
N/A
Industry
Oil & Gas Production
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
41.4M
40.9M
IPO Year
N/A
1996

Fundamental Metrics

Financial Performance
Metric
PRT
VERU
Price
$2.76
$2.22
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$22.50
AVG Volume (30 Days)
68.6K
51.7K
Earning Date
05-13-2026
05-12-2026
Dividend Yield
13.45%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$16,296,958.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$7.78
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.61
$0.36
52 Week High
$4.28
$4.59

Technical Indicators

Market Signals
Indicator
PRT
VERU
Relative Strength Index (RSI) 34.44 39.49
Support Level $2.75 $2.13
Resistance Level $4.03 $2.70
Average True Range (ATR) 0.10 0.10
MACD -0.00 -0.02
Stochastic Oscillator 3.45 3.70

Price Performance

Historical Comparison
PRT
VERU

About PRT PermRock Royalty Trust Trust Units

PermRock Royalty Trust operates as a statutory trust. Its purpose is to own the Net Profits Interest, to distribute to the Trust unitholders cash that it receives in respect of the Net Profits Interest, and to perform certain administrative functions. The Net Profits Interest entitles the trust to receive the net profits from the sale of oil and natural gas production from the underlying properties of its trustor.

About VERU Veru Inc.

Veru Inc is a late clinical-stage biopharmaceutical focused on developing medicines for the treatment of cardiometabolic and inflammatory diseases. Its drug development program consists of two late-stage new chemical entities, enobosarm and sabizabulin. Enobosarm, an oral selective androgen receptor modulator, is being developed to make weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass, and is planned for a Phase 2b PLATEAU clinical study in obesity. Sabizabulin, an oral microtubule disruptor, is being developed for the treatment of inflammation in atherosclerotic cardiovascular disease to lower high-sensitivity CRP in patients with stable coronary artery disease, with a planned Phase 2 study.

Share on Social Networks: